Novartis Gene Therapies, Inc. et al. v. Genzyme Corporation et al. > Summary
Court Case Number IPR2023-01044
Filing Date Jun 30, 2023
Institution Decision Date Jan 9, 2024
Decision Date Mar 4, 2024
Court Patent Trial and Appeal Board
Status Terminated-Settled
Administrative JudgesSheridan K. Snedden, Jeffrey N. Fredman, James A. Tartal
Judge Writing the Final DecisionSheridan K. Snedden
Claims Challenged in the Petition: 1, 2, 3, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34
Claims Instituted: 1, 2, 3, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34
Petitioner
Patent Owner
Petitioner Attorneys
5Novartis Gene Therapies, Inc.
Attorney Name: John D. Livingstone
Finnegan, Henderson, Farabow, Garrett & Dunner
Novartis Gene Therapies, Inc.
Attorney Name: Jeffrey D. Smyth
Finnegan, Henderson, Farabow, Garrett & Dunner
Novartis Gene Therapies, Inc.
Attorney Name: Amanda K. Murphy
Finnegan, Henderson, Farabow, Garrett & Dunner
Novartis Gene Therapies, Inc.
Attorney Name: Steven Berkowitz
Etehad Law, APC
Novartis Gene Therapies, Inc.
Attorney Name: William Esper
Finnegan, Henderson, Farabow, Garrett & Dunner
Patent Owner Attorneys
5Snowden Pencer/Genzyme Corporation
Attorney Name: Lisa P. Rasmussen
Sanofi
Dechert
Attorney Name: Jeffrey E. Hansen
Sanofi
Snowden Pencer/Genzyme Corporation
Attorney Name: Blaine M. Hackman
Dechert
Snowden Pencer/Genzyme Corporation
Attorney Name: Amanda K. Antons
Dechert
Snowden Pencer/Genzyme Corporation
Attorney Name: Katherine A. Helm
Dechert
Related Patents
| Doc No | Title | Issue date |
|---|---|---|
| 10429288 | Analytical ultracentrifugation for characterization of recombinant viral particles | Oct 1, 2019 |
